APA (7th ed.) Citation

M, E., S, B., V, B., H, S., U, B., C, S., . . . D, H. (2023). RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Frontiers in immunology, 14, 1286700. https://doi.org/10.3389/fimmu.2023.1286700

Chicago Style (17th ed.) Citation

M, Emde-Rajaratnam, et al. "RNA-sequencing Based First Choice of Treatment and Determination of Risk in Multiple Myeloma." Frontiers in Immunology 14 (2023): 1286700. https://doi.org/10.3389/fimmu.2023.1286700.

MLA (9th ed.) Citation

M, Emde-Rajaratnam, et al. "RNA-sequencing Based First Choice of Treatment and Determination of Risk in Multiple Myeloma." Frontiers in Immunology, vol. 14, 2023, p. 1286700, https://doi.org/10.3389/fimmu.2023.1286700.